FINWIRES · TerminalLIVE
FINWIRES

Oracle Heads Into Q1 Results With AI Investment, Stargate in Focus, RBC Capital Markets Says

By

Oracle (ORCL) is heading into its fiscal Q1 financial results with investors focused on artificial intelligence infrastructure expansion, funding needs, and Stargate uncertainty, RBC Capital Markets said in a note Thursday.

The company is scheduled to report fiscal Q1 earnings on Sept. 10.

Oracle's net cash capital expenditures of about $70 billion in fiscal year 2027, mainly to support its AI infrastructure buildout, is expected to be funded by about $40 billion of debt and equity, while about $75 billion in cumulative BYOH and prepaid contracts are expected to lower the company's financing burden, according to the note.

The Stargate arrangement adds uncertainty, with OpenAI moving from the original joint-venture structure toward bilateral capacity leases, which could change Oracle's ownership and financing obligations, the investment firm said.

The company has been using cost savings from headcount reductions to help fund its AI infrastructure buildout, analysts said, adding that while cost reallocation is more favorable than taking on additional debt or issuing equity, repeated layoffs could create execution risk.

RBC Capital Markets has a sector perform rating and $190 price target on Oracle.

Shares of Oracle were up more than 2% in Friday trading.

Price: $157.35, Change: $+3.31, Percent Change: +2.15%

Related Articles

Wire

Vaxcyte Names New Medical and Legal Chiefs Ahead of Key Phase 3 Data

Vaxcyte (PCVX) appointed Luis Jodar as chief medical officer and David McAvoy as chief legal officer, the company said on Thursday.Jodar spent 17 years at Pfizer (PFE), most recently as senior vice president and chief medical officer for Vaccines and Infectious Diseases, the company said.McAvoy joins the company from Teva Pharmaceutical (TEVA), according to a statement.The vaccine developer also said it now expects to report topline data from its phase 3 OPUS-1 trial of VAX-31 in adults by the end of October, narrowing its previous guidance of a Q4 data release.

$PCVX
Wire

eGain Fiscal Q4 Adjusted Earnings, Revenue Fall; Shares Slump After Hours

EGain (EGAN) reported fiscal Q4 adjusted earnings late Thursday of $0.08 per diluted share, down from $0.09 a year earlier.Three analysts polled by FactSet projected $0.03.Revenue in the three months ended June 30 fell to $22.2 million from $23.2 million a year earlier.Three analysts projected $21.7 million.The company expects fiscal Q1 adjusted EPS of $0.05 to $0.08 on revenue of $20.9 million to $21.4 million. Three analysts project EPS of $0.08 on revenue of $22.3 million.For fiscal 2027, eGain expects adjusted EPS of $0.04 to $0.07 on revenue of $84.5 million to $86 million. Three analysts project EPS of $0.43 on revenue of $94.1 million.EGain shares slumped 29% in after-hours trading.

$EGAN
Wire

American Outdoor Brands Fiscal Q1 Swings to Adjusted Earnings, Revenue Rises

American Outdoor Brands (AOUT) reported fiscal Q1 non-GAAP earnings late Thursday of $0.03 per diluted share, swinging from a loss $0.26 year earlier.Two analysts polled by FactSet expected a loss of $0.24.Net sales for the quarter ended July 31 were $37.3 million, up from $29.7 million a year earlier.Two analysts expected $35.6 million.For fiscal 2027, the company maintained its net sales forecast of $200 million to $210 million. Two analysts expect $205.1 million.Shares of the company rose over 16% in after-hours trading.

$AOUT